@Pledge
I do accept that the Company has many shortcomings…and my previous posts discusses some….but if you are trying to imply that previous guidance on strategic discussions has proved to be false, allow me to at least remind you of subsequent developments with Grunenthal post the article you referenced. Remember also the discussions with Novartis that emerged the following year. Silviu always stated that Covid ARDS was not the area of ARDS that Novartis originally intended to target…and that they were interested in financing all cause ARDS with high margin pricing strategy rather than a public health service emergency contribution where margins would be pressurised.
By the way, ARDS still accounts for almost 1 in 10 emergency beds in US hospitals especially as a consequence of sepsis from HAI.
In my opinion, Mesoblast has never intended to fund itself through a further pivotal Phase 3 trial in CHF. Post near term guidance from an FDA meeting on agreeing a pivotal trial surrogate primary endpoint such as 12 months ejection fraction?, I would be surprised if Mesoblast were not able to partner globally in due course for Rexlemestrocel. This might also take the form of a securitisation as Silviu will not want to give a large percentage of the upside unless absolutely necessary. I guess you think that I am looking at things with rose tinted spectacles. Maybe you’re right ? But I prefer to state what I genuinely believe to be the case , even if I have to take flak for it. Cynicism is healthy so long as you acknowledge that tremendous progress has been made along the way and reassess the risk reward on a continual basis. If you want to make an omelette, you have to break…..some legs. … OP
Please do your own research and do not rely on facts or representations in the above post when making an investment decison.
- Forums
- ASX - By Stock
- Ann: Update on Institutional Placement and Entitlement Offer
@Pledge I do accept that the Company has many shortcomings…and...
-
-
- There are more pages in this discussion • 118 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.38 |
Change
-0.080(5.50%) |
Mkt cap ! $1.569B |
Open | High | Low | Value | Volume |
$1.43 | $1.43 | $1.37 | $5.321M | 3.829M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 12214 | $1.38 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.38 | 37660 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 12214 | 1.375 |
7 | 53796 | 1.370 |
7 | 53347 | 1.365 |
14 | 192096 | 1.360 |
3 | 45165 | 1.355 |
Price($) | Vol. | No. |
---|---|---|
1.380 | 37660 | 5 |
1.385 | 25000 | 1 |
1.390 | 56973 | 4 |
1.395 | 31284 | 2 |
1.400 | 146999 | 10 |
Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
Featured News
SBW
Shekel Brainweigh reports a 50% revenue increase in its Retail Innovation suite and delivers the first batch of 20 Smart Bays to Hitachi as part of a larger order
NEWS
Deep drilling at Mulga Bill confirms gold to 500m depth, indicating further exploration potential
MSB (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online